0001415889-25-000595.txt : 20250103 0001415889-25-000595.hdr.sgml : 20250103 20250103173121 ACCESSION NUMBER: 0001415889-25-000595 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250102 FILED AS OF DATE: 20250103 DATE AS OF CHANGE: 20250103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alam Kamran CENTRAL INDEX KEY: 0001793412 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 25508068 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE, SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 form4-01032025_100118.xml X0508 4 2025-01-02 0001806310 Taysha Gene Therapies, Inc. TSHA 0001793412 Alam Kamran C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, STE 1430 DALLAS TX 75247 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2025-01-02 4 A 0 431000 0 A 1271937 D Employee Stock Option (right to buy) 1.85 2025-01-02 4 A 0 431000 0 A 2035-01-02 Common Stock 431000 431000 D Represents a restricted stock unit ("RSU") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam 2025-01-03